These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28918604)

  • 21. A single nucleotide polymorphism in SLC7A5 is associated with gastrointestinal toxicity after high-dose melphalan and autologous stem cell transplantation for multiple myeloma.
    Giglia JL; White MJ; Hart AJ; Toro JJ; Freytes CO; Holt CC; Cai Y; Williams SM; Brandt SJ
    Biol Blood Marrow Transplant; 2014 Jul; 20(7):1014-20. PubMed ID: 24704384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of frailty, melphalan pharmacokinetics, and pharmacogenetics on outcomes post autologous hematopoietic cell transplantation for multiple myeloma.
    Nampoothiri RV; Kasudhan KS; Patil AN; Malhotra P; Khadwal A; Prakash G; Jain A; Malhotra S; Verma Attri S; Varma N; Varma S; Lad DP
    Bone Marrow Transplant; 2019 Dec; 54(12):2088-2095. PubMed ID: 31406224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
    Gimsing P; Hjertner Ø; Abildgaard N; Andersen NF; Dahl TG; Gregersen H; Klausen TW; Mellqvist UH; Linder O; Lindås R; Tøffner Clausen N; Lenhoff S
    Bone Marrow Transplant; 2015 Oct; 50(10):1306-11. PubMed ID: 26121108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.
    Farag S; Jeker B; Bacher U; Mansouri Taleghani B; Mueller BU; Novak U; Pabst T
    Hematol Oncol; 2018 Oct; 36(4):671-678. PubMed ID: 30110717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
    Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
    Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.
    Voorhees PM; Usmani SZ
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):719-28. PubMed ID: 27673290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective study of dysgeusia and related symptoms in patients with multiple myeloma after autologous hematopoietic cell transplantation.
    Scordo M; Shah GL; Adintori PA; Knezevic A; Devlin SM; Buchan ML; Preston EV; Lin AP; Rodriguez NT; Carino CA; Nguyen LK; Sitner NC; Barasch A; Klang MG; Maloy MA; Mastrogiacomo B; Carlow DC; Schofield RC; Slingerland AE; Slingerland JB; Stein-Thoeringer CK; Lahoud OB; Landau HJ; Chung DJ; van den Brink MRM; Peled JU; Giralt SA
    Cancer; 2022 Nov; 128(21):3850-3859. PubMed ID: 36041227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
    Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Final outcomes of escalated melphalan 280 mg/m
    Hari P; Reece DE; Randhawa J; Flomenberg N; Howard DS; Badros AZ; Rapoport AP; Meisenberg BR; Filicko-Ohara J; Phillips GL; Vesole DH
    Bone Marrow Transplant; 2019 Feb; 54(2):293-299. PubMed ID: 29907806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acupuncture for reduction of symptom burden in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial.
    Deng G; Giralt S; Chung DJ; Landau H; Siman J; Search B; Coleton M; Vertosick E; Shapiro N; Chien C; Wang XS; Cassileth B; Mao JJ
    Support Care Cancer; 2018 Feb; 26(2):657-665. PubMed ID: 28920142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
    Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
    Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
    J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melphalan 140 mg/m
    Auner HW; Iacobelli S; Sbianchi G; Knol-Bout C; Blaise D; Russell NH; Apperley JF; Pohlreich D; Browne PV; Kobbe G; Isaksson C; Lenhoff S; Scheid C; Touzeau C; Jantunen E; Anagnostopoulos A; Yakoub-Agha I; Tanase A; Schaap N; Wiktor-Jedrzejczak W; Krejci M; Schönland SO; Morris C; Garderet L; Kröger N
    Haematologica; 2018 Mar; 103(3):514-521. PubMed ID: 29217776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
    Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
    Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outpatient Autologous Stem Cell Transplantation for Patients With Myeloma.
    Paul TM; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Nasta SD; Loren A; Frey N; Perl A; Cohen AD; Weiss BM; Stadtmauer EA; Vogl DT
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):536-40. PubMed ID: 26141214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant.
    Chang H; Samiee S; Yi QL
    Leuk Lymphoma; 2006 Jan; 47(1):43-7. PubMed ID: 16321826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Symptom prevalence and health-related quality of life in patients undergoing autologous stem cell transplantation - A longitudinal observational study.
    Stamm SL; Spichiger E; Pabst T; Bachnick S; Jeitziner MM
    Eur J Oncol Nurs; 2021 Aug; 53():101997. PubMed ID: 34294574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents.
    Su B; Zhu X; Jiang Y; Wang L; Zhao N; Ran X; Zheng X; Guo H
    Leuk Lymphoma; 2019 Jun; 60(6):1381-1388. PubMed ID: 30516074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome.
    Kumar L; Ramavath D; Kataria B; Tiwari A; Raj A; Chellapuram SK; Mookerjee A; Sahoo RK; Malik PS; Sharma A; Gupta R; Sharma OD; Biswas A; Kumar R; Thulkar S;
    Indian J Med Res; 2019 Jun; 149(6):730-739. PubMed ID: 31496525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three courses of high dose therapy. Feasibility in the treatment of multiple myeloma--a "France autogreffe" study.
    Colombat P; Milpied N; Laporte JP; Casassus P; Linassier C; Harousseu JL
    Cancer; 1994 Dec; 74(11):2930-4. PubMed ID: 7954256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.